If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
Cipla and Ethris partner for the development of mRNA-based therapies
The new facility will be able to handle four times as many patients as the previous facility.
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
A committee of two Joint Drugs Controllers has been constituted at CDSCO to monitor the process of inspection, reporting, and subsequent action to ensure compliance to the Drugs & Cosmetics Act, 1940
Mock drills are being conducted across the country to review the preparedness for management of COVID-19
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Subscribe To Our Newsletter & Stay Updated
